Health Economics›B-cell acute lymphoblastic leukemia›Relapsed or refractory

Relapsed or refractory

B-cell acute lymphoblastic leukemia · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cytarabine, Idarubicin, Rituximab Variant #01	—	R 51 949	—	—	—	—	—	—
Nilotinib monotherapy Variant #01	BCR::ABL1	R 27 206	28d	—	—	—	—	—
Imatinib monotherapy Variant #17	BCR::ABL1	R 27 014	30d	~20.0 mo	~53.0 mo	~21	~R 567 284 PFS proxy · indirect	8
High-dose Cytarabine monotherapy (HiDAC) Variant #01	—	R 26 364	—	—	6.7 mo	—	—	1
FLAG Variant #01	—	R 21 352	—	—	6.7 mo	—	—	1
7+3m Variant #01	—	R 13 063	7d	—	6.7 mo	—	—	1
Dasatinib monotherapy Variant #01	BCR::ABL1	R 12 899	28d	—	—	—	—	—
Hyper-CVAD/MA and Everolimus Variant #01	—	R 11 181	—	—	—	—	—	—
Augmented Hyper-CVAD/MA and Asparaginase Variant #01	—	R 11 088	35d	—	—	—	—	—
Cytarabine and Idarubicin Variant #01	—	R 4 599	30d	—	—	—	—	—
Cytarabine monotherapy Variant #01	—	R 366	30d	—	—	—	—	—
Blinatumomab monotherapy N/A - secondary systemic drug	BCR::ABL1	R 18	28d	—	7.7 mo	—	—	1
Blinatumomab monotherapy N/A - secondary systemic drug	—	R 18	28d	—	7.7 mo	—	—	1
Bosutinib monotherapy Variant #01 Partial	BCR::ABL1	—	28d	—	—	—	—	—
Cytarabine and Mitoxantrone (MC) Partial	—	—	—	—	—	—	—	—
Ponatinib monotherapy Variant #01 Partial	BCR::ABL1	—	28d	—	—	—	—	—
BCG vaccine monotherapy Variant #01 Partial	—	—	30d	—	~38.6 mo	—	—	1
Pentostatin monotherapy Variant #01 Partial	—	—	14d	—	—	—	—	—
TBI Variant #01 Partial	—	—	—	—	—	—	—	4
Clofarabine monotherapy Variant #01 Partial	—	—	42d	—	—	—	—	1
Inotuzumab ozogamicin monotherapy Variant #01 Partial	—	—	28d	—	7.7 mo	—	—	1
Tisagenlecleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—
Vincristine liposomal monotherapy Variant #01 Partial	—	—	7d	—	—	—	—	—
Brexucabtagene autoleucel monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—

24 of 24 regimens shown